0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Human Health Effects Sign in to save

Challenges and Future Prospects: A Benefaction of Phytoconstituents on Molecular Targets Pertaining to Alzheimer’s Disease

International Journal of Pharmaceutical Investigation 2023 28 citations ? Citation count from OpenAlex, updated daily. May differ slightly from the publisher's own count. Score: 55 ? 0–100 AI score estimating relevance to the microplastics field. Papers below 30 are filtered from public browse.
Himanshu Sharma, Phool Chandra

Summary

This review explores the potential of plant-derived compounds as therapeutic agents for Alzheimer's disease, examining how various phytochemicals interact with molecular targets involved in the condition. Researchers summarize evidence on natural compounds that may help address inflammation, oxidative stress, and protein buildup in the brain. The study highlights the need for further research to translate these preliminary findings into viable treatment approaches.

Himanshu Sharma and Phool Chandra Author informationPDFCitations Corresponding author. Correspondence: Mr. Himanshu Sharma Reseach Scholar, Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad-244001, Uttar Pradesh, INDIA. Email: amitsharmaaligarh786@gmail.com Author Notes Received July 15, 2023; Revised October 09, 2023; Accepted October 25, 2023. Copyright and License information Copyright ©2024 Phcog.Net This is

Sign in to start a discussion.

More Papers Like This

Article Tier 2

Bioactive Compounds and Their Derivatives: An Insight into Prospective Phytotherapeutic Approach against Alzheimer’s Disease

Researchers reviewed natural bioactive compounds from plant sources for their potential neuroprotective effects related to Alzheimer's disease. The study highlights how these compounds may modulate molecular mechanisms involved in disease development, while noting challenges such as limited bioavailability and blood-brain barrier permeability.

Article Tier 2

Neuroprotective compounds from marine invertebrates

Researchers reviewed biologically active compounds found in marine invertebrates like sponges, sea cucumbers, and coral, many of which show potential for treating neuroinflammatory diseases such as Alzheimer's and Parkinson's by targeting key proteins involved in brain inflammation and cell death. While promising, the review notes that challenges around sustainable sourcing and the need for more clinical trials remain significant hurdles before these marine compounds reach patients.

Article Tier 2

Alzheimer’s disease: the role of extrinsic factors in its development, an investigation of the environmental enigma

This review examines how environmental contaminants, including microplastics, may contribute to Alzheimer's disease risk. Along with air pollutants, toxic metals, and pesticides, plastics and microplastics are identified as potential risk factors that may promote brain inflammation and neurodegeneration. The review explores the molecular mechanisms behind these effects and suggests strategies to reduce the brain health impacts of environmental contaminants.

Article Tier 2

The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment

This review examines the emerging role of a protein called PCSK9, best known for regulating cholesterol levels, in the development of Alzheimer's disease. Evidence indicates that PCSK9 may contribute to brain inflammation, oxidative stress, and the buildup of amyloid plaques that characterize the disease. The authors suggest that therapies targeting PCSK9, including existing cholesterol-lowering drugs, could potentially offer a new approach to Alzheimer's treatment.

Clinical Trial Tier 1

Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond

This review examines why clinical trials targeting amyloid-beta for Alzheimer's disease have largely failed, and explores emerging alternatives including tau-targeted therapies, neuroinflammation modulation, and gene therapy. The study is not directly related to microplastic research.

Share this paper